ATCC's High Containment Facility Renovations in Support of NIAID and Pandemic Preparedness

ATCC 的高密闭设施改造支持 NIAID 和流行病防范

基本信息

批准号：
10611743
负责人：
Rebecca Bradford
金额：
$ 386.27万
依托单位：
AMERICAN TYPE CULTURE COLLECTION
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-16 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10611743
关键词：
2019-nCoV 3-Dimensional Air Conditioning Alphavirus American Type Culture Collection Animals Antiviral Agents Basic Science Biological Assay COVID-19 Categories Collaborations Communicable Diseases Communities Computer Security Containment Coronavirus Country Data Decontamination Development Diagnostic Dimensions Disease Outbreaks Doctor of Philosophy Ebola Ebola virus Emerging Communicable Diseases Equipment FDA approved Family Fostering Foundations Funding Goals Health Heating Human Infection Infectious Agent Infectious Diseases Research Influenza A Virus, H1N1 Subtype Institution Laboratories Logistics Longevity Microbiology Middle East Respiratory Syndrome Mission Modernization National Institute of Allergy and Infectious Disease Orthobunyavirus Pathogenesis Peptides Pharmaceutical Preparations Production Protocols documentation Publications RNA RNA Viruses Readiness Reagent Regulation Research Research Personnel Research Support Resource Sharing Resources Scientist Services Ships System Therapeutic Translating Translational Research Vaccines Viral Virginia Virus ZIKA Zika Virus antimicrobial base biobank biocontainment facility biodefense emerging pathogen facility renovation human pathogen in vitro Model influenzavirus novel pandemic disease pandemic preparedness pathogen pre-clinical priority pathogen product development programs repaired response response biomarker screening small molecule square foot tool two-dimensional ventilation working group

项目摘要

Project Summary: The proposed project aims to renovate ATCC's High Containment Facility (HCF) at the American Type Culture Collection (ATCC) in Manassas, Virginia. ATCC's 7,500 ft2 biocontainment facility was built in 2007 with funding from NIAID and has been dedicated to developing infectious disease strains and reagents needed to rapidly advance diagnostics, vaccines, and therapeutics against priority pathogens. Since 2003, ATCC has partnered with NIAID to centralize and provide critical scientific resources through the Biodefense and Emerging Infections Resources (BEI Resources) program. The NIAID established BEI Resources to provide the global research community with reagents, tools, and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, and other microbiological materials relevant to human health. Over the past 18 years, ATCC has provided over 1,360,000 reagents to over 14,000 investigators at 3,740 institutions in 119 countries spanning over 500 human pathogens in NIAID's priority portfolio. During this period, BEI Resources has provided critical materials for vital disease outbreaks, including H1N1, MERS, Ebola, and Zika. Over the past two years, ATCC has rapidly created more than 690 SARS-CoV-2 products; acquired, produced, and authenticated more than 165 stocks of SARS-CoV-2 for both general research and challenge studies; and shipped more than 86,000 research reagents to over 2,800 researchers in more than 70 countries for the development of countermeasures and basic research. The material provided by BEI Resources has been cited in more than 1,800 SARS-CoV-2 publications since February of 2020. In addition, ATCC has fostered collaboration and partnerships across NIAID programs and external working groups to share resources, information, and data to accelerate discoveries and harmonize scientific approaches for pandemic response and preparedness. ATCC's high containment facility houses laboratories essential for BSL-3 and Select Agent infectious disease research, product development, and large-scale reagent production for the research community. This proposal aims to renovate and upgrade the HVAC, decontamination, and security systems. The renovations also include upgrades to fixed equipment and interior finishing in the facility. The renovations will modernize the facility for use by 40 Ph.D. ATCC scientists, collaborators, and laboratory support staff. The products and services developed in the facility will support thousands of scientists globally each year to prepare and respond to pandemics. ATCC is seeking this opportunity for engagement with the NIAID to invest in this facility which has been foundational for the nation's pandemic response and preparedness.

项目概要：拟议项目旨在翻新 ATCC 在美国的高密闭设施 (HCF) 位于弗吉尼亚州马纳萨斯的典型培养物保藏中心 (ATCC)。 ATCC 的 7,500 平方英尺生物防护设施于 2007 年在 NIAID 的资助下建成，一直致力于开发传染病快速推进诊断、疫苗和治疗所需的疾病菌株和试剂针对优先病原体。自 2003 年以来，ATCC 与 NIAID 合作，集中并提供通过生物防御和新发感染资源（BEI 资源）计划。 NIAID 建立了 BEI 资源来提供全球研究提供用于研究 A、B 和 C 类优先级的试剂、工具和信息的社区病原体、新出现的传染病病原体以及其他相关微生物材料人类健康。 18年来，ATCC已为超过1,360,000个国家提供了超过1,360,000份试剂 119 个国家 3,740 个机构的 14,000 名研究人员涵盖 500 多种人类病原体在 NIAID 的优先投资组合中。在此期间，BEI Resources 为重大疾病爆发，包括 H1N1、MERS、埃博拉和寨卡。近两年来，ATCC 迅速创造了690多种SARS-CoV-2产品；获取、生产和验证超过 165 个 SARS-CoV-2 库存用于一般研究和挑战研究；和向 70 多个国家的 2,800 多名研究人员运送了 86,000 多种研究试剂制定对策和基础研究。材料由BEI提供自 2020 年 2 月以来，已有 1,800 多篇 SARS-CoV-2 出版物引用了这些资源。此外，ATCC 还促进了 NIAID 项目之间的合作和伙伴关系，外部工作组共享资源、信息和数据，以加速发现和协调流行病应对和防备的科学方法。 ATCC 的高密闭设施设有 BSL-3 和 Select Agent 所必需的实验室传染病研究、产品开发和大规模试剂生产研究社区。该提案旨在翻新和升级暖通空调、净化、和安全系统。翻新工程还包括固定设备和内部的升级在设施中完成。此次翻修将使该设施现代化，供 40 名博士使用。航空航天中心科学家、合作者和实验室支持人员。开发的产品和服务该设施每年将支持全球数千名科学家准备和应对流行病。 ATCC 正在寻求与 NIAID 合作的机会来投资这一领域该设施是国家应对大流行病和做好准备的基础。